WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that it will host a conference call
at 4:30 p.m. ET on Thursday, November 3, 2016 to discuss third quarter
2016 financial results and provide a general corporate update.
The live call can be accessed by dialing +1-888-424-8151 for U.S.
callers and +1-847-585-4422 for international callers five minutes prior
to the start of the call and by providing the passcode 8448237. A live
webcast of the conference call will be available online from the
Investors section of the Company’s website at www.ovascience.com.
A replay of the conference call will be available from 7:00 p.m. ET on
Thursday, November 3, 2016 through 11:59 p.m. ET on Thursday, November
10, 2016, and may be accessed by visiting OvaScience’s website or by
dialing +1-888-843-7419 for U.S. callers and +1-630-652-3042 for
international callers. The replay access code is 8448237.
OvaScienceSM (NASDAQ: OVAS)
is a global fertility company dedicated to improving treatment options
for women around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience is developing the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S. For more
information, please visit www.ovascience.com
or follow us on Twitter
Media and Investor Contact: